Development of a Complementation Assay to Monitor Pan-Coronavirus 3C-like Protease Activity.

Akhil Chameettachal, Alice Duchon, Matthew A Brown, Jonathan M O Rawson, Vinay K Pathak, Wei-Shau Hu

Abstract read

In one paragraph

Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Akhil ChameettachalViral Recombination Section, HIV Dynamics and Replication Program, National Cancer Institute, Frederick, MD 21702, USA.ORCID 0000-0003-1944-6726

Alice DuchonViral Recombination Section, HIV Dynamics and Replication Program, National Cancer Institute, Frederick, MD 21702, USA.ORCID 0000-0002-9297-6291

Matthew A BrownViral Recombination Section, HIV Dynamics and Replication Program, National Cancer Institute, Frederick, MD 21702, USA.

Jonathan M O RawsonViral Recombination Section, HIV Dynamics and Replication Program, National Cancer Institute, Frederick, MD 21702, USA.

Vinay K PathakViral Mutation Section, HIV Dynamics and Replication Program, National Cancer Institute, Frederick, MD 21702, USA.

Wei-Shau HuViral Recombination Section, HIV Dynamics and Replication Program, National Cancer Institute, Frederick, MD 21702, USA.

Funding

NIH HHS Intramural researchNIH HHS ITAC grant

6 · The paper itself

Abstract

Coronaviruses pose a global pandemic threat, making development of a pan-coronavirus inhibitor crucial for preparedness and containment in the event of a new coronavirus outbreak. The 3C-like protease (3CL

Indexed as

CoronavirusCoronavirus 3C Proteases3C Viral ProteasesAnimalsAntiviral AgentsCell LineGenes, ReporterHumansLuciferasesSARS-CoV-23C Viral ProteasesAntiviral AgentsCoronavirus 3C ProteasesLuciferases3CLprocoronavirusesluciferase reporter assaypan-coronavirus inhibitor

Identifiers

PMID41754577

DOI10.3390/v18020234

PMCPMC12945148

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.